{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:31:11Z","timestamp":1792791071127,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00228-025-03847-1","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T09:33:18Z","timestamp":1746610398000},"page":"1001-1015","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antithrombotic therapy for secondary stroke prevention in patients with cancer: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"81","author":[{"given":"Leonardo Zumerkorn","family":"Pipek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela Farias Vidigal","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Isabel","family":"Coronel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Mayor","family":"Basto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Diogo","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"3847_CR1","first-page":"5172","volume":"10","author":"NG Zaorsky","year":"2019","unstructured":"Zaorsky NG, Zhang Y, Tchelebi LT et al (2019) Stroke among cancer patients Nat Commun 10:5172","journal-title":"Stroke among cancer patients Nat Commun"},{"key":"3847_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.thromres.2023.01.005","volume":"222","author":"Y Gon","year":"2023","unstructured":"Gon Y, Zha L, Sasaki T et al (2023) Stroke mortality in cancer survivors: a population-based study in Japan. Thromb Res 222:140\u2013148","journal-title":"Thromb Res"},{"key":"3847_CR3","first-page":"779","volume":"54","author":"E Dardiotis","year":"2019","unstructured":"Dardiotis E, Aloizou A-M, Markoula S et al (2019) Cancer-associated stroke: pathophysiology, detection and management (Review). Int J Oncol 54:779\u2013796","journal-title":"Int J Oncol"},{"key":"3847_CR4","first-page":"23","volume":"3","author":"S Hawbaker","year":"2012","unstructured":"Hawbaker S (2012) Venous thromboembolism in the cancer population: pathology, risk, and prevention. J Adv Pract Oncol 3:23\u201333","journal-title":"J Adv Pract Oncol"},{"key":"3847_CR5","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/ana.25227","volume":"83","author":"BB Navi","year":"2018","unstructured":"Navi BB, Iadecola C (2018) Ischemic stroke in cancer patients: a review of an underappreciated pathology. Ann Neurol 83:873\u2013883","journal-title":"Ann Neurol"},{"key":"3847_CR6","doi-asserted-by":"publisher","first-page":"e513","DOI":"10.1212\/WNL.0000000000011264","volume":"96","author":"F Zhang","year":"2021","unstructured":"Zhang F, Wang K, Du P et al (2021) Risk of stroke in cancer survivors: a meta-analysis of population-based cohort studies. Neurology 96:e513\u2013e526","journal-title":"Neurology"},{"key":"3847_CR7","doi-asserted-by":"publisher","first-page":"e88283","DOI":"10.1371\/journal.pone.0088283","volume":"9","author":"K-K Lau","year":"2014","unstructured":"Lau K-K, Wong Y-K, Teo K-C et al (2014) Stroke patients with a past history of cancer are at increased risk of recurrent stroke and cardiovascular mortality. PLoS ONE 9:e88283","journal-title":"PLoS ONE"},{"key":"3847_CR8","doi-asserted-by":"publisher","first-page":"966190","DOI":"10.3389\/fneur.2022.966190","volume":"13","author":"R Lun","year":"2022","unstructured":"Lun R, Roy DC, Hao Y et al (2022) Incidence of stroke in the first year after diagnosis of cancer-a systematic review and meta-analysis. Front Neurol 13:966190","journal-title":"Front Neurol"},{"key":"3847_CR9","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1161\/STROKEAHA.109.571356","volume":"41","author":"SG Kim","year":"2010","unstructured":"Kim SG, Hong JM, Kim HY et al (2010) Ischemic stroke in cancer patients with and without conventional mechanisms: a multicenter study in Korea. Stroke 41:798\u2013801","journal-title":"Stroke"},{"key":"3847_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s11883-012-0250-3","volume":"14","author":"AJ Velander","year":"2012","unstructured":"Velander AJ, DeAngelis LM, Navi BB (2012) Intracranial hemorrhage in patients with cancer. Curr Atheroscler Rep 14:373\u2013381","journal-title":"Curr Atheroscler Rep"},{"key":"3847_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.thromres.2024.03.019","volume":"237","author":"T Kawano","year":"2024","unstructured":"Kawano T, Mackman N (2024) Cancer patients and ischemic stroke. Thromb Res 237:155\u2013162","journal-title":"Thromb Res"},{"key":"3847_CR12","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","volume":"52","author":"DO Kleindorfer","year":"2021","unstructured":"Kleindorfer DO, Towfighi A, Chaturvedi S et al (2021) 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association. Stroke 52:e364\u2013e467","journal-title":"Stroke"},{"key":"3847_CR13","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/ene.14172","volume":"27","author":"N Martinez-Majander","year":"2020","unstructured":"Martinez-Majander N, Ntaios G, Liu YY et al (2020) Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial. Eur J Neurol 27:841\u2013848","journal-title":"Eur J Neurol"},{"key":"3847_CR14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jamaneurol.2017.4211","volume":"75","author":"BB Navi","year":"2018","unstructured":"Navi BB, Marshall RS, Bobrow D et al (2018) Enoxaparin vs aspirin in patients with cancer and ischemic stroke: the TEACH pilot randomized clinical trial. JAMA Neurol 75:379\u2013381","journal-title":"JAMA Neurol"},{"key":"3847_CR15","doi-asserted-by":"publisher","first-page":"10407","DOI":"10.1007\/s00520-022-07433-4","volume":"30","author":"S Wu","year":"2022","unstructured":"Wu S, Lv M, Chen J et al (2022) Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis. Support Care Cancer 30:10407\u201310420","journal-title":"Support Care Cancer"},{"key":"3847_CR16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"3847_CR17","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919","journal-title":"BMJ"},{"key":"3847_CR18","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"key":"3847_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v106.i02","volume":"106","author":"S Balduzzi","year":"2023","unstructured":"Balduzzi S, R\u00fccker G, Nikolakopoulou A et al (2023) netmeta: an R package for network meta-analysis using frequentist methods. J Stat Softw 106:1\u201340","journal-title":"J Stat Softw"},{"key":"3847_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G R\u00fccker","year":"2015","unstructured":"R\u00fccker G, Schwarzer G (2015) Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol 15:58","journal-title":"BMC Med Res Methodol"},{"key":"3847_CR21","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1001\/jamaneurol.2024.2404","volume":"81","author":"BB Navi","year":"2024","unstructured":"Navi BB, Zhang C, Miller B et al (2024) Apixaban vs aspirin in patients with cancer and cryptogenic stroke: a post hoc analysis of the ARCADIA randomized clinical trial. JAMA Neurol 81:958\u2013965","journal-title":"JAMA Neurol"},{"key":"3847_CR22","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1177\/17474930241239266","volume":"19","author":"J-W Chung","year":"2024","unstructured":"Chung J-W, Hwang J, Kim HJ et al (2024) Edoxaban for the treatment of hypercoagulability and cerebral thromboembolism associated with cancer: a randomized clinical trial of biomarker targets. Int J Stroke 19:645\u2013653","journal-title":"Int J Stroke"},{"key":"3847_CR23","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1161\/01.STR.25.6.1215","volume":"25","author":"S Chaturvedi","year":"1994","unstructured":"Chaturvedi S, Ansell J, Recht L (1994) Should cerebral ischemic events in cancer patients be considered a manifestation of hypercoagulability? Stroke 25:1215\u20131218","journal-title":"Stroke"},{"key":"3847_CR24","doi-asserted-by":"publisher","first-page":"502089","DOI":"10.1155\/2015\/502089","volume":"2015","author":"H Jang","year":"2015","unstructured":"Jang H, Lee JJ, Lee MJ et al (2015) Comparison of enoxaparin and warfarin for secondary prevention of cancer-associated stroke. J Oncol 2015:502089","journal-title":"J Oncol"},{"key":"3847_CR25","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.07.029","volume":"26","author":"K-W Nam","year":"2017","unstructured":"Nam K-W, Kim CK, Kim TJ et al (2017) Treatment of cryptogenic stroke with active cancer with a new oral anticoagulant. J Stroke Cerebrovasc Dis 26:2976\u20132980","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"3847_CR26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.10.012","volume":"28","author":"H Kawano","year":"2019","unstructured":"Kawano H, Honda Y, Amano T et al (2019) Subcutaneous heparin therapy for patients with cancer-associated stroke. J Stroke Cerebrovasc Dis 28:399\u2013404","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"3847_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.thromres.2021.08.016","volume":"206","author":"G Yamaura","year":"2021","unstructured":"Yamaura G, Ito T, Miyaji Y et al (2021) Therapeutic efficacy of heparin and direct factor Xa inhibitors in cancer-associated cryptogenic ischemic stroke with venous thromboembolism. Thromb Res 206:99\u2013103","journal-title":"Thromb Res"},{"key":"3847_CR28","doi-asserted-by":"publisher","first-page":"868137","DOI":"10.3389\/fneur.2022.868137","volume":"13","author":"S Nakajima","year":"2022","unstructured":"Nakajima S, Kawano H, Yamashiro K et al (2022) Post-treatment plasma D-dimer levels are associated with short-term outcomes in patients with cancer-associated stroke. Front Neurol 13:868137","journal-title":"Front Neurol"},{"key":"3847_CR29","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.04.021","volume":"27","author":"H Naito","year":"2018","unstructured":"Naito H, Nezu T, Hosomi N et al (2018) Antithrombotic therapy strategy for cancer-associated ischemic stroke: a case series of 26 patients. J Stroke Cerebrovasc Dis 27:e206\u2013e211","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"3847_CR30","doi-asserted-by":"publisher","first-page":"100123","DOI":"10.1016\/j.rpth.2023.100123","volume":"7","author":"Y Hisada","year":"2023","unstructured":"Hisada Y, Mackman N (2023) Mechanisms of cancer-associated thrombosis. Res Pract Thromb Haemost 7:100123","journal-title":"Res Pract Thromb Haemost"},{"key":"3847_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/jth.15544","volume":"20","author":"T Sasano","year":"2022","unstructured":"Sasano T, Gonzalez-Delgado R, Mu\u00f1oz NM et al (2022) Podoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer. J Thromb Haemost 20:104\u2013114","journal-title":"J Thromb Haemost"},{"key":"3847_CR32","doi-asserted-by":"publisher","unstructured":"Hisada Y, Mackman N (2021) Tissue factor and extracellular vesicles: activation of coagulation and impact on survival in cancer. Cancers (Basel) 13. https:\/\/doi.org\/10.3390\/cancers13153839","DOI":"10.3390\/cancers13153839"},{"key":"3847_CR33","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1161\/STROKEAHA.120.032002","volume":"52","author":"BB Navi","year":"2021","unstructured":"Navi BB, Kasner SE, Elkind MSV et al (2021) Cancer and embolic stroke of undetermined source. Stroke 52:1121\u20131130","journal-title":"Stroke"},{"key":"3847_CR34","doi-asserted-by":"publisher","first-page":"4378","DOI":"10.1074\/jbc.273.8.4378","volume":"273","author":"RJ Baugh","year":"1998","unstructured":"Baugh RJ, Broze GJ Jr, Krishnaswamy S (1998) Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem 273:4378\u20134386","journal-title":"J Biol Chem"},{"issue":"Suppl 1","key":"3847_CR35","first-page":"103","volume":"23","author":"U Abildgaard","year":"1993","unstructured":"Abildgaard U (1993) Heparin\/low molecular weight heparin and tissue factor pathway inhibitor. Haemostasis 23(Suppl 1):103\u2013106","journal-title":"Haemostasis"},{"key":"3847_CR36","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P et al (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378:615\u2013624","journal-title":"N Engl J Med"},{"key":"3847_CR37","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1378\/chest.14-0402","volume":"147","author":"MC Vedovati","year":"2015","unstructured":"Vedovati MC, Germini F, Agnelli G, Becattini C (2015) Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 147:475\u2013483","journal-title":"Chest"},{"key":"3847_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","volume":"81","author":"CD Khairani","year":"2023","unstructured":"Khairani CD, Bejjani A, Piazza G et al (2023) Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials. J Am Coll Cardiol 81:16\u201330","journal-title":"J Am Coll Cardiol"},{"key":"3847_CR39","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4103\/tcmj.tcmj_55_19","volume":"31","author":"J-Y Hsu","year":"2019","unstructured":"Hsu J-Y, Liu A-B (2019) Anticoagulants for cancer-associated ischemic stroke. Tzu Chi Med J 31:144\u2013148","journal-title":"Tzu Chi Med J"},{"key":"3847_CR40","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1161\/STROKEAHA.120.033217","volume":"52","author":"K-H Choi","year":"2021","unstructured":"Choi K-H, Kim J-H, Kim J-M et al (2021) D -dimer level as a predictor of recurrent stroke in patients with embolic stroke of undetermined source. Stroke 52:2292\u20132301","journal-title":"Stroke"},{"key":"3847_CR41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000535644","volume":"14","author":"J Fujinami","year":"2024","unstructured":"Fujinami J, Nagakane Y, Fujikawa K et al (2024) D-dimer trends predict recurrent stroke in patients with cancer-related hypercoagulability. Cerebrovasc Dis Extra 14:9\u201315","journal-title":"Cerebrovasc Dis Extra"},{"key":"3847_CR42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1212\/WNL.0000000000000539","volume":"83","author":"BB Navi","year":"2014","unstructured":"Navi BB, Singer S, Merkler AE et al (2014) Recurrent thromboembolic events after ischemic stroke in patients with cancer. Neurology 83:26\u201333","journal-title":"Neurology"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03847-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03847-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03847-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T18:02:21Z","timestamp":1749578541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03847-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3847"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03847-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}